DE60234318D1 - Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors - Google Patents

Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Info

Publication number
DE60234318D1
DE60234318D1 DE60234318T DE60234318T DE60234318D1 DE 60234318 D1 DE60234318 D1 DE 60234318D1 DE 60234318 T DE60234318 T DE 60234318T DE 60234318 T DE60234318 T DE 60234318T DE 60234318 D1 DE60234318 D1 DE 60234318D1
Authority
DE
Germany
Prior art keywords
treatment
receptor
lpa
lpa receptor
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234318T
Other languages
English (en)
Inventor
Shinji Nakade
Daikichi Fukushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60234318D1 publication Critical patent/DE60234318D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60234318T 2001-02-08 2002-02-07 Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors Expired - Lifetime DE60234318D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001031827 2001-02-08
PCT/JP2002/001025 WO2002062389A1 (fr) 2001-02-08 2002-02-07 Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa

Publications (1)

Publication Number Publication Date
DE60234318D1 true DE60234318D1 (de) 2009-12-24

Family

ID=18895852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234318T Expired - Lifetime DE60234318D1 (de) 2001-02-08 2002-02-07 Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors

Country Status (6)

Country Link
US (1) US7288558B2 (de)
EP (1) EP1364659B1 (de)
JP (1) JP4396808B2 (de)
AT (1) ATE447970T1 (de)
DE (1) DE60234318D1 (de)
WO (1) WO2002062389A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007991A1 (fr) * 2001-07-17 2003-01-30 Ono Pharmaceutical Co., Ltd. Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa
WO2004002530A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 慢性疾患治療剤
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
TW200408393A (en) * 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
JP4523265B2 (ja) * 2002-11-13 2010-08-11 旭化成ファーマ株式会社 排尿障害治療用口腔内崩壊製剤
AU2004213297B2 (en) 2003-02-18 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
US20060160887A1 (en) * 2003-07-16 2006-07-20 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
WO2005012269A1 (ja) 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
ATE528276T1 (de) 2003-12-19 2011-10-15 Ono Pharmaceutical Co Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen
WO2006009092A1 (ja) 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
CA2583846C (en) 2004-10-12 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
KR20090041424A (ko) 2006-08-08 2009-04-28 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체 및 그것들을 유효성분으로 하는 면역 억제제
KR101339976B1 (ko) * 2006-08-08 2013-12-10 교린 세이야꾸 가부시키 가이샤 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 ｓ1ｐ 수용체 조절제
US8466683B2 (en) * 2006-12-14 2013-06-18 Schlumberger Technology Corporation Determining properties of earth formations using the electromagnetic coupling tensor
EP2175843B1 (de) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung
EP2042179A1 (de) * 2007-09-26 2009-04-01 sanofi-aventis Neue therapeutische Verwendung adrenerger alpha-1-Rezeptorantagonisten
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
EP2324852B1 (de) * 2008-08-07 2015-07-08 Nagasaki University Therapeutischer oder prophylaktischer wirkstoff für generalisiertes schmerzsyndrom
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
BR112012006686B8 (pt) 2009-09-25 2021-05-25 Astellas Pharma Inc compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US9119878B2 (en) * 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
CN103189378B (zh) 2010-09-02 2016-03-02 默克专利股份公司 作为lpa受体拮抗剂的吡唑并吡啶酮衍生物
CA2810706C (en) 2010-09-24 2018-06-12 Astellas Pharma Inc. Substituted amide compound
AU2011338561A1 (en) 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
JP6107650B2 (ja) 2011-03-18 2017-04-05 小野薬品工業株式会社 テトラヒドロカルボリン誘導体
JP2014513077A (ja) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
US20130150426A1 (en) 2011-11-22 2013-06-13 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
DK2940013T3 (en) 2012-12-28 2018-03-26 Ube Industries HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
US10596127B2 (en) * 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
AU2014232383B2 (en) 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
EP3710438B1 (de) 2017-12-19 2021-10-20 Bristol-Myers Squibb Company Triazol-n-verknüpfte carbamoylcyclohexylsäuren als lpa-antagonisten
EP3728222B1 (de) 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl-säure pyrazolazine als lpa-antagonisten
CN111479807A (zh) 2017-12-19 2020-07-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
KR20200100719A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
EA202091505A1 (ru) 2017-12-19 2020-09-22 Бристол-Маерс Сквибб Компани Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
SG11202005701VA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
ES2925626T3 (es) 2017-12-19 2022-10-19 Bristol Myers Squibb Co Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA
KR102062052B1 (ko) * 2018-03-20 2020-01-03 일양약품주식회사 베타네콜 서방성 제제 및 이의 제조방법
AU2019282274A1 (en) 2018-06-07 2021-01-28 Idorsia Pharmaceuticals Ltd Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis
JP7429224B2 (ja) 2018-09-18 2024-02-07 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘプチル酸
CN113473985A (zh) 2018-09-18 2021-10-01 百时美施贵宝公司 作为lpa拮抗剂的环戊酸
US20210317131A1 (en) 2018-09-18 2021-10-14 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
EP3986551A1 (de) 2019-06-18 2022-04-27 Bristol-Myers Squibb Company Triazolcarbonsäuren als lpa-antagonisten
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
KR20220024549A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 카르복실산
CN114599641A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的环丁基羧酸
US20230097871A1 (en) 2019-07-30 2023-03-30 Taisho Pharmaceutical Co., Ltd. Urea compound for antagonizing lpa1 receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653679B2 (ja) * 1987-11-11 1994-07-20 帝人株式会社 尿道内圧増強剤
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
AUPN862996A0 (en) * 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
IL120302A0 (en) 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
JPH1135558A (ja) * 1997-07-18 1999-02-09 Zeria Pharmaceut Co Ltd ３−ベンゾイルインドール誘導体及びそれらを含有する医薬
WO1999035259A1 (en) * 1997-12-30 1999-07-15 Nps Allelix Corp. Identification of lysolipid receptors involved in inflammatory response
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
DK1258484T3 (da) * 2000-02-18 2009-04-20 Kyowa Hakko Kirin Co Ltd Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
EP1263752B1 (de) * 2000-03-17 2007-12-05 The University Of Tennessee Research Corporation Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
EP1372655B1 (de) * 2001-03-02 2008-10-01 Merck Frosst Canada Ltd. Cathepsincystein-proteasehemmer

Also Published As

Publication number Publication date
EP1364659B1 (de) 2009-11-11
JP4396808B2 (ja) 2010-01-13
US7288558B2 (en) 2007-10-30
JPWO2002062389A1 (ja) 2004-06-03
EP1364659A1 (de) 2003-11-26
US20040067908A1 (en) 2004-04-08
ATE447970T1 (de) 2009-11-15
EP1364659A4 (de) 2006-03-29
WO2002062389A1 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
DE60234318D1 (de) Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
CY1107214T1 (el) Αγωνιστες και ανταγωνιστες υποδοχεων λυσοφωσφατιδικου οξεος (lpa) kai τροποι χρησης
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
DE60037892D1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE205493T1 (de) N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60103384D1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE218860T1 (de) Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
AU2342397A (en) N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
AU2002321232A1 (en) Treatment of hair follicle with neurokinin 1 receptor antagonists
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BR0309435A (pt) Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DK0880540T3 (da) 17-Beta-cyclopropyl(amino/oxy)-4-azasteroider som aktive inhibitorer af testosteron 5-alfa-reduktase og C17-20-lyase
DE60121459D1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DK1366033T3 (da) Kemiske forbindelser
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition